Inositol, a dietary supplement the body makes, is studied mainly for blood sugar and hormonal health. Its clearest effects are modest improvements in fasting blood sugar, blood fats and blood pressure, mostly in a common ovarian hormone disorder, clustered metabolic risk factors and pregnancy. For people already improving metabolic health through diet and exercise, it is a low-risk, low-cost addition whose measurable effect lies in blood sugar regulation, not aging. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting glucose | 70–99 mg/dL | Expected to fall; safety check with diabetes drugs |
| Fasting insulin | 2.6–24.9 µIU/mL | Expected to fall with better insulin sensitivity |
| HOMA-IR | No established target; track change from own baseline | Expected to fall |
| Triglycerides | Below 150 mg/dL | Expected to fall |
| LDL cholesterol | Below 100 mg/dL | Expected to fall slightly |
| Total testosterone (women with PCOS) | 15–70 ng/dL | Expected to fall |
| SHBG (women with PCOS) | 18–144 nmol/L | Expected to rise |
| TSH (people on levothyroxine using selenium combinations) | 0.4–4.0 mIU/L | Safety check for an additive fall |
| Home blood pressure | Not specified in the ER | Cardiovascular baseline |
Cadence: Baseline before starting, including one week of home blood pressure readings; fasting glucose and insulin at 3 months, then every 6–12 months together with a lipid panel; androgen tests at 3–6 months in women with PCOS; home glucose checks during the first 2–4 weeks with insulin or sulfonylureas; TSH recheck at 3 months with levothyroxine and a selenium combination